Home > Boards > US Listed > Medical - Healthcare > Precision Therapeutics Inc. (AIPT)

Precision Therapeutics’ Subsidiary, Helomics® Corporation, and SpeciCare, Inc.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Paullee Member Profile
 
Followed By 13
Posts 1,760
Boards Moderated 0
Alias Born 11/25/03
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 6/19/2019 4:16:43 PM
Amended Current Report Filing (8-k/a) Edgar (US Regulatory) - 6/18/2019 4:16:57 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/13/2019 8:46:12 AM
Predictive Oncology Inc. (Formerly Precision Therapeutics) Names Amelia Warner, Pharm.D., RPh, as Interim Chief Operating Off... GlobeNewswire Inc. - 6/12/2019 8:00:00 AM
Precision Therapeutics Announces Corporate Name Change To Predictive Oncology Inc. GlobeNewswire Inc. - 6/11/2019 8:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/4/2019 4:12:42 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/4/2019 4:01:53 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/28/2019 5:45:51 PM
Amended Statement of Beneficial Ownership (sc 13d/a) Edgar (US Regulatory) - 5/24/2019 4:10:17 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/24/2019 3:47:52 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/23/2019 5:15:04 PM
Precision Therapeutics’ Helomics Division Selected by AccuGenomics as Preferred Lab Partner for NIIMBL Grant GlobeNewswire Inc. - 5/21/2019 8:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/17/2019 4:03:32 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/17/2019 9:02:17 AM
Precision Therapeutics Gains Extension for Nasdaq Compliance GlobeNewswire Inc. - 5/17/2019 9:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/15/2019 4:35:58 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/15/2019 4:07:54 PM
Precision Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire Inc. - 5/15/2019 4:05:00 PM
Precision Therapeutics to Report First Quarter 2019 Financial Results and Provide Company Update on Wednesday, May 15, 2019 GlobeNewswire Inc. - 5/13/2019 1:30:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/8/2019 5:17:36 PM
Statement of Beneficial Ownership (sc 13d) Edgar (US Regulatory) - 4/24/2019 4:56:15 PM
Statement of Beneficial Ownership (sc 13d) Edgar (US Regulatory) - 4/24/2019 4:31:32 PM
Precision Therapeutics’ Subsidiary Helomics and National Alopecia Areata Foundation Sign Services Agreement to Provide Next... GlobeNewswire Inc. - 4/18/2019 8:45:00 AM
Precision Therapeutics’ Subsidiary TumorGenesis and its Partner 48Hour Discovery Inc. Receive Alberta Innovates Product Dem... GlobeNewswire Inc. - 4/16/2019 8:45:00 AM
Precision Therapeutics’ Subsidiary, Helomics® Corporation, and SpeciCare, Inc. to Study Innovative Personalized Medicine... GlobeNewswire Inc. - 4/11/2019 8:45:00 AM
Paullee   Thursday, 04/11/19 09:02:53 AM
Re: None
Post # of 4057 
Precision Therapeutics’ Subsidiary, Helomics® Corporation, and SpeciCare, Inc. to Study Innovative Personalized Medicine Opportunities for Cancer Patients
GlobeNewswire•April 11, 2019
Helomics to provide CRO services and its D-CHIP artificial intelligence (AI) platform to SpeciCare for their PIONEER Initiative functional precision medicine trial

PITTSBURGH, April 11, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (AIPT) (“Precision” or “the Company”) today announced that its wholly-owned subsidiary, Helomics® Corporation (Helomics), which provides personalized medicine solutions and boutique CRO services for clients in the pharmaceutical, diagnostic, and biotechnology industries, and SpeciCare, an innovative Georgia-based company connecting cancer patients to new treatment options only available through storing the patient’s live tumor tissue, have signed an agreement for Helomics to provide CRO services and its D-CHIP artificial intelligence (AI) platform for a functional precision medicine study sponsored by SpeciCare.

“SpeciCare is at the forefront of a renewed interest in functional precision medicine, which has been core to our personalized oncology approach for many years. We are excited to work with SpeciCare on their PIONEER initiative study, which will utilize Helomics’ core functional precision medicine technology of live tumor drug profiling assays (TruTumor™) and genomic profiling coupled with our AI-driven bioinformatics platform, D-CHIP,” commented Gerald J. Vardzel Jr., president of Helomics. “This collaboration further demonstrates the value of our CRO services and D-CHIP platform, both to generate revenue, and advance personalized medicine to improve patient treatment and outcomes.”

Functional precision medicine goes beyond pure genomics to test live tumor tissue from the patient with a variety of approaches that interrogate how the tumor behaves, such as when challenged with potential therapies. Traditional genomics-only approaches often do not provide clinically actionable results outside of a handful of approved genomic biomarkers and associated drugs, limiting clinicians’ options for individualizing therapy.

Dr Ken Dixon, Founder and CEO of SpeciCare said, “Our PIONEER initiative study aims to demonstrate the value of functional precision medicine approaches on living tissue stored from the patient, to better connect patients to new treatment options. Partnering with Helomics, who have over a decade of experience in testing living tumor tissue, aligns well with these study goals.”

“We continue to enable AI and data-driven precision medicine and welcome the opportunity to provide CRO services to SpeciCare,” said Dr. Carl Schwartz, CEO of Precision Therapeutics. “We envision this PIONEER study will demonstrate the added value of the functional precision medicine approach for clinicians and anticipate more such collaborations to help bring true personalized medicine to patients worldwide.”

About Precision Therapeutics Inc.

Precision Therapeutics applies artificial intelligence to rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in partnership with pharmaceutical companies. Additionally, the company provides automated fluid waste disposal systems for hospitals and clinics.

For additional information, please visit www.precisiontherapeutics.com.

About SpeciCare

B4CC Inc., doing business as SpeciCare, is an innovative company connecting cancer patients to new treatment options only available through storing the patient’s live tumor tissue. Serving as the missing link connecting routine clinical care to the most advanced medical treatments and the research community, SpeciCare’s goal is to arm patients with new options and innovative solutions that enhance their quality of life and improve their chances of survival. SpeciCare serves as a catalyst in the development of the cancer treatment field and utilization of research for the benefit of the cancer patient. For more information, please visit specicare.com or call 833- 242-2873.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist